Skip to main
ZVRA

ZVRA Stock Forecast & Price Target

ZVRA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zevra Therapeutics is a commercial-stage company with a promising late-stage pipeline that focuses on rare diseases. Its recent successful commercialization of miglustat, a treatment for Niemann-Pick disease type C (NPC), shows the company's potential to bring life-changing therapeutics to underserved patient populations. Furthermore, its ongoing clinical trials for other rare diseases, such as Urea Cycle Disorders and vEDS, offer potential for future growth and expansion. The company also has a strong safety profile and diversified revenue streams, mitigating potential risks such as payer pushback or competition from similar treatments.

Bears say

Zevra Therapeutics is a commercial-stage biotech company with one marketed product for the treatment of Niemann-Pick disease type C (NPC), a rare neurodegenerative disease. However, with only 73% of diagnosed patients currently being treated with the product, there is limited potential for revenue growth in the short term. Additionally, the company's late-stage pipeline and potential future earnings are uncertain, making it a risky investment for those seeking long-term gains.

ZVRA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zevra Therapeutics Inc (ZVRA) Forecast

Analysts have given ZVRA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ZVRA has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zevra Therapeutics Inc (ZVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.